REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of “Moderate Buy” by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $30.3750.

A number of research analysts have recently weighed in on RGNX shares. Stifel Nicolaus increased their price objective on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a research note on Thursday, January 29th. Finally, Barclays began coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective on the stock.

Institutional Trading of REGENXBIO

A number of hedge funds have recently added to or reduced their stakes in RGNX. Voss Capital LP boosted its holdings in shares of REGENXBIO by 47.4% during the 2nd quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock worth $4,721,000 after purchasing an additional 185,000 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 23.2% during the third quarter. Assenagon Asset Management S.A. now owns 705,403 shares of the biotechnology company’s stock worth $6,807,000 after buying an additional 132,942 shares in the last quarter. Squarepoint Ops LLC lifted its position in REGENXBIO by 2,049.0% during the second quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock worth $1,800,000 after buying an additional 209,084 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in REGENXBIO during the second quarter worth $220,000. Finally, 22NW LP grew its holdings in REGENXBIO by 38.1% in the 2nd quarter. 22NW LP now owns 923,679 shares of the biotechnology company’s stock valued at $7,583,000 after buying an additional 255,000 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $10.31 on Tuesday. The business’s 50-day moving average is $13.43 and its 200 day moving average is $11.43. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $16.19. The firm has a market capitalization of $521.89 million, a P/E ratio of -2.97 and a beta of 1.05.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.